Difference between revisions of "Colorectal cancer - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://doi.org/10.1016/s0140-673697033588" to "https://doi.org/10.1016/s0140-6736(97)03358-8") |
m |
||
(24 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | <span id="BackToTop"></span> |
+ | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
+ | [[#top|Back to Top]] | ||
+ | </div> | ||
+ | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the [[Colorectal_cancer|main colorectal cancer page]] for current regimens. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Metastatic disease, first-line= | =Metastatic disease, first-line= | ||
==Fluorouracil & Methotrexate (MF) {{#subobject:bcd024|Regimen=1}}== | ==Fluorouracil & Methotrexate (MF) {{#subobject:bcd024|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | MF: '''<u>M</u>'''ethotrexate & '''<u>F</u>'''luorouracil |
+ | <div class="toccolours" style="background-color:#ee6b6e"> | ||
===Regimen {{#subobject:909280|Variant=1}}=== | ===Regimen {{#subobject:909280|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 20: | Line 25: | ||
|1992-1994 | |1992-1994 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
− | |[[#MF_. | + | |[[#MF_.26_PALA_999|MF & PALA]] |
| style="background-color:#ffffbf" |Did not meet endpoints of RR/PFS/OS | | style="background-color:#ffffbf" |Did not meet endpoints of RR/PFS/OS | ||
|- | |- | ||
Line 26: | Line 31: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 30 mg/kg/day IV continuous infusion over 48 hours, started on day 1 (total dose per cycle: 60 mg/kg) |
− | *[[Methotrexate (MTX)]] | + | *[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once on day 1, '''given first''' |
+ | '''7-day cycle for 3 cycles, then 14-day cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; [[Study_Groups#EORTC|EORTC]] Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. [https://doi.org/10.1016/s0959-8049(02)00662-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12565987 PubMed] | + | # Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; [[Study_Groups#EORTC|EORTC]] Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. [https://doi.org/10.1016/s0959-8049(02)00662-7 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/12565987/ PubMed] |
+ | |||
==Fluorouracil & Mitomycin {{#subobject:29baf5|Regimen=1}}== | ==Fluorouracil & Mitomycin {{#subobject:29baf5|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:e41b97|Variant=1}}=== | ===Regimen {{#subobject:e41b97|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.3816/ccc.2004.n.004 Price et al. 2004] |
|1996-1998 | |1996-1998 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
Line 50: | Line 57: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion over 42 days, started on day 1 (total dose per cycle: 12,600 mg/m<sup>2</sup>) |
− | *[[Mitomycin (Mutamycin)]] | + | *[[Mitomycin (Mutamycin)]] 7 mg/m<sup>2</sup> (maximum dose of 14 mg) IV once on day 1 |
+ | '''42-day cycle for up to 4 cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. [https:// | + | # Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. [https://doi.org/10.3816/ccc.2004.n.004 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15025796/ PubMed] |
+ | |||
==Fluorouracil & Semustine {{#subobject:ddfd74|Regimen=1}}== | ==Fluorouracil & Semustine {{#subobject:ddfd74|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:4df123|Variant=1}}=== | ===Regimen {{#subobject:4df123|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 66: | Line 75: | ||
|- | |- | ||
|[https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S Baker et al. 1976] | |[https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S Baker et al. 1976] | ||
− | |1973-1974 | + | |1973-03 to 1974-10 |
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
|[[Colon_cancer#Fluorouracil_monotherapy|5-FU]] | |[[Colon_cancer#Fluorouracil_monotherapy|5-FU]] | ||
Line 74: | Line 83: | ||
|NR | |NR | ||
|style="background-color:#1a9851"|Phase 3 (E-switch-ic) | |style="background-color:#1a9851"|Phase 3 (E-switch-ic) | ||
− | |1. [[#Fluorouracil.2C_Semustine. | + | |1. [[#Fluorouracil.2C_Semustine.2C_Vincristine_999|5-FU, Semustine, Vincristine]]<br>2. [[#Dacarbazine.2C_Fluorouracil.2C_Semustine_999|5-FU, Dacarbazine, Semustine]]<br>3. [[#Dacarbazine.2C_Fluorouracil.2C_Semustine.2C_Vincristine_999|5-FU, Dacarbazine, Semustine, Vincristine]]<br>4. [[#Fluorouracil_.26_Hydroxyurea_999|5-FU & Hydrea]] |
| style="background-color:#ffffbf" |Did not meet endpoints of RR/OS | | style="background-color:#ffffbf" |Did not meet endpoints of RR/OS | ||
|- | |- | ||
Line 80: | Line 89: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Fluorouracil (5-FU)]] | + | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36 |
− | *[[Semustine (MeCCNU)]] | + | *[[Semustine (MeCCNU)]] 175 mg/m<sup>2</sup> PO once on day 1 |
+ | '''42-day cycles''' | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. [https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S link to original article] [https://pubmed.ncbi.nlm.nih.gov/779949 PubMed] | + | # Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. [https://doi.org/10.1002/1097-0142(197607)38:1%3C1::AID-CNCR2820380102%3E3.0.CO;2-S link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/779949/ PubMed] |
− | # '''ECOG E4275:''' Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. [https://doi.org/10.1002/1097-0142(19820415)49:8%3C1555::AID-CNCR2820490807%3E3.0.CO;2-C link to original article] [https://pubmed.ncbi.nlm.nih.gov/7039814 PubMed] | + | # '''ECOG E4275:''' Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. [https://doi.org/10.1002/1097-0142(19820415)49:8%3C1555::AID-CNCR2820490807%3E3.0.CO;2-C link to original article] [https://pubmed.ncbi.nlm.nih.gov/7039814/ PubMed] |
+ | |||
==FOLFOX chronotherapy {{#subobject:7239a0|Regimen=1}}== | ==FOLFOX chronotherapy {{#subobject:7239a0|Regimen=1}}== | ||
− | FOLFOX: '''<u>FOL</u>'''inic acid, '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin | + | FOLFOX: '''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>OX</u>'''aliplatin |
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:0af678|Variant=1}}=== | ===Regimen {{#subobject:0af678|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
− | !style="width: 20%"| | + | !style="width: 20%"|Dates of enrollment |
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
!style="width: 20%"|Comparator | !style="width: 20%"|Comparator | ||
Line 100: | Line 111: | ||
|1991-1993 | |1991-1993 | ||
|style="background-color:#1a9851"|Phase 3 (E-switch-ic) | |style="background-color:#1a9851"|Phase 3 (E-switch-ic) | ||
− | |[[# | + | |[[#FOLFOX_888|FOLFOX]]; CI |
| style="background-color:#1a9850" |Superior TTF | | style="background-color:#1a9850" |Superior TTF | ||
|- | |- | ||
Line 107: | Line 118: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
− | *[[Folinic acid | + | *[[Leucovorin (Folinic acid)]] 300 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with 5-FU''' |
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with leucovorin''' | *[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given second, with leucovorin''' | ||
*[[Oxaliplatin (Eloxatin)]] 20 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given first''' | *[[Oxaliplatin (Eloxatin)]] 20 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5, '''given first''' | ||
Line 113: | Line 124: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. [https://doi.org/10.1016/s0140-6736(97)03358-8 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9291901 PubMed] | + | # Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. [https://doi.org/10.1016/s0140-6736(97)03358-8 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9291901/ PubMed] |
+ | |||
+ | ==Raltitrexed monotherapy {{#subobject:rclb7e|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#ee6b6e"> | ||
+ | ===Regimen {{#subobject:3dcd8b|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Dates of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/0959-8049(95)00502-1 Cunningham et al. 1995] | ||
+ | |1993-11 to 1994-06 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | ||
+ | |[[Colorectal_cancer#FULV_3|FULV]]; Mayo Clinic regimen (LDLV) | ||
+ | | style="background-color:#ffffbf" |Did not meet primary endpoint of TTP | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.1998.16.9.2943 Cocconi et al. 1998] | ||
+ | |1995-07 to 1996-02 | ||
+ | | style="background-color:#1a9851" |Phase 3 (E-switch-ooc) | ||
+ | |[[Colorectal_cancer#FULV_3|FULV]]; HDLV | ||
+ | | style="background-color:#d73027" |Inferior TTP | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Chemotherapy==== | ||
+ | *[[Raltitrexed (Tomudex)]] 3 mg/mg<sup>2</sup> IV once on day 1 | ||
+ | '''21-day cycles''' | ||
+ | </div></div> | ||
+ | |||
+ | ===References=== | ||
+ | #Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K; The 'Tomudex' Colorectal Cancer Study Group. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer. 1995 Nov;31A(12):1945-54. [https://doi.org/10.1016/0959-8049(95)00502-1 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/8562146/ PubMed] | ||
+ | ##'''Update:''' Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G; "Tomudex" Colorectal Cancer Study Group. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol. 1996 Nov;7(9):961-5. Erratum in: Ann Oncol 1997 Apr;8(4):407. [https://doi.org/10.1093/oxfordjournals.annonc.a010800 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9006748/ PubMed] | ||
+ | #Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM; Tomudex Colorectal Cancer Study Group. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol. 1998 Sep;16(9):2943-52. [https://doi.org/10.1200/jco.1998.16.9.2943 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/9738562/ PubMed] | ||
+ | #'''MRC CR06:''' Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ; British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2002 May 4;359(9317):1555-63. [https://doi.org/10.1016/S0140-6736(02)08514-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12047964/ PubMed] [https://clinicaltrials.gov/study/NCT00002893 NCT00002893] | ||
+ | #'''FFCD 9601:''' Ducreux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P, Leduc B, Berger C, Dunant A, Fournet J, Bedenne L; FFCD. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer: final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Oncology. 2006;70(3):222-30. Epub 2006 Jun 30. [https://doi.org/10.1159/000094357 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16816536/ PubMed] | ||
[[Category:Colorectal cancer regimens]] | [[Category:Colorectal cancer regimens]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] |
Latest revision as of 00:43, 30 June 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main colorectal cancer page for current regimens.
5 regimens on this page
5 variants on this page
|
Metastatic disease, first-line
Fluorouracil & Methotrexate (MF)
MF: Methotrexate & Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Wils et al. 2003 | 1992-1994 | Phase 3 (C) | MF & PALA | Did not meet endpoints of RR/PFS/OS |
Chemotherapy
- Fluorouracil (5-FU) 30 mg/kg/day IV continuous infusion over 48 hours, started on day 1 (total dose per cycle: 60 mg/kg)
- Methotrexate (MTX) 40 mg/m2 IV once on day 1, given first
7-day cycle for 3 cycles, then 14-day cycles
References
- Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. link to original article contains dosing details in manuscript PubMed
Fluorouracil & Mitomycin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Price et al. 2004 | 1996-1998 | Phase 3 (C) | Fluorouracil & Mitomycin; chronomodulated | Did not meet endpoints of FFS/OS |
Chemotherapy
- Fluorouracil (5-FU) 300 mg/m2/day IV continuous infusion over 42 days, started on day 1 (total dose per cycle: 12,600 mg/m2)
- Mitomycin (Mutamycin) 7 mg/m2 (maximum dose of 14 mg) IV once on day 1
42-day cycle for up to 4 cycles
References
- Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. link to original article contains dosing details in manuscript PubMed
Fluorouracil & Semustine
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Baker et al. 1976 | 1973-03 to 1974-10 | Phase 3 (C) | 5-FU | Superior ORR |
Engstrom et al. 1982 (ECOG E4275) | NR | Phase 3 (E-switch-ic) | 1. 5-FU, Semustine, Vincristine 2. 5-FU, Dacarbazine, Semustine 3. 5-FU, Dacarbazine, Semustine, Vincristine 4. 5-FU & Hydrea |
Did not meet endpoints of RR/OS |
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV once per day on days 1, 8, 15, 22, 29, 36
- Semustine (MeCCNU) 175 mg/m2 PO once on day 1
42-day cycles
References
- Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. link to original article contains dosing details in abstract PubMed
- ECOG E4275: Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. link to original article PubMed
FOLFOX chronotherapy
FOLFOX: FOLinic acid (Leucovorin), Fluorouracil, OXaliplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lévi et al. 1997 | 1991-1993 | Phase 3 (E-switch-ic) | FOLFOX; CI | Superior TTF |
Note: This schedule is "chronomodulated"; see paper for details.
Chemotherapy
- Leucovorin (Folinic acid) 300 mg/m2 IV over 12 hours once per day on days 1 to 5, given second, with 5-FU
- Fluorouracil (5-FU) 600 mg/m2 IV over 12 hours once per day on days 1 to 5, given second, with leucovorin
- Oxaliplatin (Eloxatin) 20 mg/m2 IV over 12 hours once per day on days 1 to 5, given first
21-day cycles
References
- Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. link to original article contains dosing details in manuscript PubMed
Raltitrexed monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cunningham et al. 1995 | 1993-11 to 1994-06 | Phase 3 (E-switch-ooc) | FULV; Mayo Clinic regimen (LDLV) | Did not meet primary endpoint of TTP |
Cocconi et al. 1998 | 1995-07 to 1996-02 | Phase 3 (E-switch-ooc) | FULV; HDLV | Inferior TTP |
References
- Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K; The 'Tomudex' Colorectal Cancer Study Group. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer. 1995 Nov;31A(12):1945-54. link to original article contains dosing details in manuscript PubMed
- Update: Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G; "Tomudex" Colorectal Cancer Study Group. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol. 1996 Nov;7(9):961-5. Erratum in: Ann Oncol 1997 Apr;8(4):407. link to original article PubMed
- Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM; Tomudex Colorectal Cancer Study Group. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol. 1998 Sep;16(9):2943-52. link to original article contains dosing details in manuscript PubMed
- MRC CR06: Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ; British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2002 May 4;359(9317):1555-63. link to original article PubMed NCT00002893
- FFCD 9601: Ducreux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P, Leduc B, Berger C, Dunant A, Fournet J, Bedenne L; FFCD. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer: final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Oncology. 2006;70(3):222-30. Epub 2006 Jun 30. link to original article PubMed